What is Redcliffe Genetics?
Founded in 2004 and headquartered in Noida, India, Redcliffe Genetics operates at the forefront of genetic sequencing and diagnostics. The company leverages advanced technology to provide critical insights into genetic health, positioning itself as a key player in the rapidly evolving healthcare landscape. Its focus on diagnostics and sequencing addresses a growing demand for personalized medicine and early disease detection.
How much funding has Redcliffe Genetics raised?
Redcliffe Genetics has raised a total of $61M across 1 funding round:
Series B
$61M
Series B (2022): $61M with participation from LeapFrog Investments
Key Investors in Redcliffe Genetics
LeapFrog Investments
LeapFrog Investments is a prominent investment firm focused on backing exceptional businesses in emerging markets, particularly in Africa and Asia. Their strategic investment in Redcliffe Genetics suggests a focus on companies poised for significant growth and positive societal impact within the healthcare sector.
What's next for Redcliffe Genetics?
The substantial enterprise-level funding, including the recent major strategic investment, signals a new phase of accelerated growth and expansion for Redcliffe Genetics. This capital infusion is expected to fuel further research and development, enhance its diagnostic capabilities, and broaden its market reach, both domestically and internationally. The company is poised to solidify its position as a leader in genetic diagnostics, driving innovation and improving patient outcomes through advanced genetic insights.
See full Redcliffe Genetics company page
